The Cancer Genome Atlas (TCGA) analyzed GBM and established four molecular subtypes [15] defined by IDH1 mutation and methylation status, [16] and more recently three subtypes which takes into consideration tumor purity and heterogeneity, [17] but has not yet led to new therapies. Here, IDH1 is linked to glioblastoma.